Oral peptide delivery specialist Cyprumed GmbH is about to find out if the high bioavailability of its tablet formulations seen in animal models will translate across to humans, after signing a $493 million license and option agreement with Merck & Co. Inc.
At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.
FK506-binding protein-like (FKBPL) is an immunophilin protein family member with critical functions in physiological and pathological angiogenesis. Its therapeutic peptide derivative AD-01, currently a preclinical peptide candidate, targets angiogenesis via CD44. AD-01 acts both as a vascular stabilizer and an anti-inflammatory agent under pro-inflammatory conditions.
Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients with obesity, metabolic and fibrotic disorders.
Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide currently in phase II development as an intravenous treatment of eosinophilic esophagitis.
Centauri Therapeutics Ltd. has selected its first clinical candidate in the ABX-01 program to treat gram-negative bacterial lung infections. Based on the company’s Alphamer platform, the broad-spectrum antimicrobial peptide has been selected to treat clinically prevalent and multidrug-resistant bacterial strains.
The nuclear protein charged amino acid-rich leucine zipper 1 (Crlz-1) has been shown to play a role in the rapid proliferative stages of B-cell development, being targeted by the canonical Wnt/β-catenin signaling pathway.
Researchers from Southwest Jiaotong University published the discovery of novel high affinity peptides against the protein of human DNA binding domain of FOXM1 (FOXM1-DBD) to be developed for the treatment of cancer.
Pseudomonas aeruginosa is included in the World Health Organization’s Bacterial Priority Pathogen List 2024 because of its concerning ability to acquire and develop high levels of antimicrobial resistance. New-in-class antimicrobial options specifically targeting multidrug-resistant (MDR) P. aeruginosa are lacking.
Researchers from the Mayo Clinic described the efficacy of NPA-7, a potential first-in-class multivalent fusion protein comprising a sequence of 22 amino acids of human BNP fused to the Mas receptor agonist Ang 1-7.
RSS
